What's in Advanced Accelerator Applications's pipeline?

Advanced Accelerator Applications has 8 drugs in our index: 4 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Advanced Accelerator Applications's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/advanced-accelerator-applications.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Advanced Accelerator Applications — Portfolio Competitive Intelligence Brief

Advanced Accelerator Applications pipeline: 4 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 1 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
L-Lysine	LYSINE	marketed	lysine	Glutathione reductase, mitochondrial	Metabolic
PSMA-11	PSMA-11	marketed			Other
LUTATHERA	LUTATHERA	marketed
arginine/lysine	arginine/lysine	marketed			Immunology
177Lu-DOTA0-Tyr3-Octreotate	177Lu-DOTA0-Tyr3-Octreotate	phase 3	Radiolabeled peptide; somatostatin receptor agonist	Somatostatin receptor 2 (SSTR2)	Oncology

Therapeutic area mix

Immunology · 1
Metabolic · 1
Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Advanced Accelerator Applications:

Cite this brief

Drug Landscape (2026). Advanced Accelerator Applications — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/advanced-accelerator-applications. Accessed 2026-05-13.